Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252922 | 0.81 | KCNN4 (0.35) | CYP2D6ALDH1A1CYP2C19HSD17B10MAPK1 | |
| SCHEMBL2257330 | 0.79 | KCNN4 (0.46) | TSHRCYP2D6ALDH1A1CYP2C19HSD17B10 | |
| SCHEMBL3220633 | 0.74 | TSHR (0.44) | TSHRCYP2D6ALDH1A1CYP2C19HSD17B10 | |
| SCHEMBL28467487 | 0.69 | CYP2D6 (0.44) | CYP2D6ALDH1A1CYP2C19HSD17B10MAPK1 | |
| SCHEMBL3223142 | 0.66 | ALDH1A1 (0.44) | TSHRCYP2D6ALDH1A1CYP2C19HSD17B10 | |
| SCHEMBL1552018 | 0.63 | MAPK1 (0.38) | CYP2D6ALDH1A1CYP2C19HSD17B10MAPK1 | |
| SCHEMBL8089565 | 0.62 | TSHR (0.50) | TSHRCYP2D6ALDH1A1CYP2C19HSD17B10 | |
| SCHEMBL3676402 | 0.62 | MAPK1 (0.50) | TSHRALDH1A1CYP2C19MAPK1KCNN4 | |
| SCHEMBL28175240 | 0.62 | TSHR (0.50) | TSHRCYP2D6ALDH1A1CYP2C19HSD17B10 | |
| SCHEMBL27655597 | 0.62 | TSHR (0.50) | TSHRCYP2D6ALDH1A1CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | SANKYO COMPANY, LIMITED (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1568704-A1 | NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | NSUN2, RNGTT, NSUN3 | TSHR 1870/4885CYP2D6 1351/4885ALDH1A1 820/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | TSHR 1214/4885CYP2D6 3074/4885ALDH1A1 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.